摘要
目的比较婴幼儿喘息发作患者给予免疫调节剂干预治疗后喘息发作的变化,探讨免疫调节剂对婴幼儿喘息预后的影响。方法43例符合入选标准的首次发作喘息患儿首诊时随机分为两组,均予吸氧、糖皮质激素吸入、支气管舒张剂等对症支持治疗。其中24例为免疫调节剂干预组:泛福舒,3.5mg/d,每月服10d,疗程3月;基础治疗组19例:仅给予布地奈德气雾剂吸入,200μg/d,疗程3月。同时选择10例同期在儿童保健门诊做健康体检的婴幼儿为健康对照组。并于我院儿科哮喘门诊随诊观察或电话跟踪随诊1年,记录喘息再发的次数和呼吸道感染的次数。结果两组患儿1年内反复喘息发作的观察比较,泛福舒干预组患儿喘息发作≥3次的比率为25%,明显低于基础治疗组(63.2%),差异有显著性(χ2=6.344,P<0.05);在呼吸道感染方面,泛福舒干预组呼吸道感染的次数和健康对照组相当,差异无显著性(t=0.72,P>0.05),基础治疗组呼吸道感染的次数和健康对照组及泛福舒干预组相比较,明显增加,差异有显著性(t值分别为3.11、3.92,P<0.05)。结论免疫调节剂能够有效减少婴幼儿喘息发作患者再次发作的次数,减少呼吸道感染的发生,降低婴幼儿喘息发作患者发展为哮喘的风险。
Objective To assess the value of immunoregulants in improving the prognosis of infants with wheezing.Methods Forty-three infants with wheezing with given oxygen support,injection or inhalation of glucocorticosteroids or bronchodilatator to relieve the symptoms.Of these infants,24 received immunoregulant treatment with bronchovaxom at the daily dose of 3.5 mg for 10 days every a month for a treatment course of 3 months.The other 19 infants were managed with budesonide aerosol at 200 μg once or twice daily for 3 months（basic treatment group）.All the infants were followed up for 1 year to record the number of wheezing episode and infections.Ten healthy infants were also included in this study as the control group.Results In infants with bronchovaxom treatment,25% reported more than 3 wheezing episodes within the 1-year follow-up,a rate significantly lower than that in the control group（63.2%,χ^2=6.344,P〈0.05）.The episodes of respiratory infection were similar between bronchovaxom group and the healthy control group（t=0.72,P〉0.05）,but significantly higher in the basic treatment group than in bronchovaxom and the healthy control group（t=3.11 and 3.92,respectively.P〈0.05）.Conclusion Bronchovaxom can effectively reduce the recurrence of wheezing and respiratory infections in the infants with wheezing attack to reduce the risks of asthma development.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2007年第10期1612-1613,共2页
Journal of Southern Medical University
